Accelerating Crofelemer Development
Jaguar Health to Use AI for Rare Disease Drug Research
The company aims to accelerate development of crofelemer for intestinal failure using AI-driven genetic modeling.
A laboratory monitor showing a digital DNA model and data analytics charts representing AI-driven drug development in a modern medical research facility.
Photo: Kronos Digital News
Jaguar Health announced plans to utilize artificial intelligence platforms to develop treatments for rare intestinal failure conditions [1]. The company will use AI to establish links between genetics and how these diseases progress [2]. This initiative focuses on accelerating the development of its lead drug candidate, crofelemer [1][3]. By leveraging AI, Jaguar Health aims to enhance the anticipated commercialization of its therapies [1]. The technology helps researchers identify patterns in complex genetic data [3]. These insights may provide credible evidence to support clinical trials for rare diseases [2].
Editorial notes
Transparency note
Drafted with LLM; human-edited
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
biospace.com
https://www.biospace.com/artificial-intelligence-ai-platforms-could-enhance-jaguar-health-s-development-and-anticipated-commercialization-of-crofelemer-for-rare-disease-intestinal-failure-if-programs/
- 2.↗
investing.com
https://www.investing.com/news/company-news/jaguar-health-plans-ai-use-for-rare-disease-drug-development-93CH-3375782
- 3.↗
stocktitan.net
https://www.stocktitan.net/news/JAGX/jaguar-health-plans-to-leverage-ai-platforms-to-support-development-m1u6r7y2v6z8.html
Related stories
View all
Topics
About the author
Kronos Digital News Desk covers accelerating crofelemer development and editorial analysis for Kronos Digital News.